Skip to content

Soft Peripheral Contact Lens for Eye Elongation Control (SPACE):1-year Results of a Double-blinded Randomized Con-trolled Trial

Soft Peripheral Contact Lens for Eye Elongation Control (SPACE):1-year Results of a Double-blinded Randomized Con-trolled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05733884
Enrollment
100
Registered
2023-02-17
Start date
2020-12-09
Completion date
2022-05-04
Last updated
2023-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Soft Contact Lens

Keywords

axial length, children, myopia control, soft contact lens, clinical trials

Brief summary

A prospective, randomised, double-blinded clinical trial was conducted including 115 children (55 male and 60 female) aged 8 to 15 years. The newest multifocal contact lenses were assigned to experimental group, and another commercial dual-focus optical designed contact lenses were assigned to control group to be worn for at least 8 hours per day, 7 days a week, for a period of 1 year. All contact lenses were replaced with new lenses every day. Measurements obtained using a LogMAR vision meter, including automated computerised optometry, handheld retinoscopy, high (96%) and low (12%) contrast sensitivity visual acuity values at a distance, and near-visible acuity values were used to evaluate the corneal curvature using a corneal mapper. Additionally, the axial length(AXL) of the eye was measured, and the tear quality was assessed using a slit lamp, including tear break-up time, tear river height, and observation of blink frequency. Furthermore, the eye's anterior surface was examined by slit lamp using the Efron grading scale.

Interventions

soft contact lens

Sponsors

Chung Shan Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
8 Years to 15 Years
Healthy volunteers
Yes

Inclusion criteria

* Subjects must be between the ages of 8 and 15 (both 8 and 15 years old). * Subject's best corrected visual acuity must be at least LogMAR 0.10 or higher in both eyes. * The subject's eyes must be healthy and normal, and normal eyes is defined as having the following characteristics. 1. Based on the slit-lamp examination results of the screening clinic, determined that the infection of the conjunctiva, eyelids and accessory organs was less than Grade 2 (mild). 2. No structural abnormality of the eyelid, conjunctiva or accessory organ tissue. 3. Slit lamp findings must be less than Grade 1 (mild) and the cornea must not show: edema, staining, clouding, or vascularization according to the slit lamp findings of the screening clinic. 4. No iritis. 5. There are no other active eye diseases that are not suitable for contact lens wear. * No topical eye drops are currently being used. * The subject and his/her legal representative (if the subject is under 20 years old) are willing to sign the subject's consent form. * Legal guardians of subjects under 12 years of age are willing to sign the informed consent form. * Meet the following refractive criteria determined by cycloplegic autorefraction at baseline 1. Spherical equivalent refractive error: between -0.75 and -6.00 D inclusive 2. Astigmatism: ≤-0.75 D 3. Anisometropia: \<1.00 D

Exclusion criteria

* Participants with certain eye diseases that may affect their eye health or may be aggravated by the test product. * Those who are unable to comply with regular tracking and inspection. * Subject is currently participating, or has participated in another drug trial within 4 weeks prior to enrollment in this trial. * Subject has undergone any eye surgery or corneal surgery. * Subject has used systemic steroids, other systemic medications that may significantly affect vision or recovery, ophthalmic steroids, eye ointments, or pupil dilators (except for examination pupil dilators) within 2 weeks prior to trial entry. * Those who are unable to cooperate with regular tracking and inspection. * Participants with poor hygiene practices that may compromise safety during the trial or be inconsistent with the participant's best interests.

Design outcomes

Primary

MeasureTime frameDescription
Spherical Equivalent Refraction (SER)12 monthsThe change in spherical equivalent refraction (SER) measured by cycloplegic autorefraction over 12 months.

Secondary

MeasureTime frameDescription
Axial Eye Length (AXL)12 monthsThe change in axial eye length (AXL) measured over 12 months. Axial length is measured after cycloplegia using optical biometry.

Other

MeasureTime frameDescription
Primary safety Endpoints12 monthsAll dispensed eyes over all follow-up visits. Measured on a scale of 0-4 with 0=no findings and 4=severe findings. Epithelial edema, epithelial microcysts, corneal staining, limbal & bulbar injection, conjunctival abnormalities, corneal neovascularization and infiltrates will be measured.(700GL Slit Lamp, Takagi Europe)

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026